EP3811932A1 — Dosage form of apalutamide
Assigned to Zentiva KS · Expires 2021-04-28 · 5y expired
What this patent protects
The present invention provides a solid dosage form of apalutamide which comprises a solid dispersion of apalutamide comprising or consisting of apalutamide and hydroxypropyl methylcellulose phthalate, preferably in weight ratio about 1:3.Such solid dosage form has an improved dis…
USPTO Abstract
The present invention provides a solid dosage form of apalutamide which comprises a solid dispersion of apalutamide comprising or consisting of apalutamide and hydroxypropyl methylcellulose phthalate, preferably in weight ratio about 1:3.Such solid dosage form has an improved dissolution profile and allows to achieve a higher drug loading and a smaller size of dosage form.
Drugs covered by this patent
- Erleada (apalutamide) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.